The Lancet HIV in conversation with

Richard Wu on a phase 1 trial of a broadly neutralising antibody for HIV

The Lancet Group

In HIV prevention and treatment, broadly neutralising antibodies have so far failed failed to deliver on their potential; could N6LS buck the trend? Richard Wu talks about a phase 1 study with some promising results.

Read the full article:

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00041-4/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanhiv

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv